Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study

Xiaofeng Chen; Quan Zhu; Yiqian Liu; Ping Liu; Yongmei Yin; Renhua Guo; Kaihua Lu; Yanhong Gu; Lianke Liu; Jinghua Wang; Zhaoxia Wang; Oluf Dimitri Røe; Yongqian Shu; Lingjun Zhu

doi:10.1371/journal.pone.0095897

Loading metrics

Open Access

Peer-reviewed

Research Article

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study

Xiaofeng Chen ,

Contributed equally to this work with: Xiaofeng Chen, Quan Zhu

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Quan Zhu ,

Contributed equally to this work with: Xiaofeng Chen, Quan Zhu

Affiliation Department of Cardiothoracic Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Yiqian Liu,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Ping Liu,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Yongmei Yin,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Renhua Guo,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Kaihua Lu,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Yanhong Gu,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Lianke Liu,

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Jinghua Wang,

Affiliation Department of Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
⨯
Zhaoxia Wang,

Affiliation Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Oluf Dimitri Røe,

Affiliations Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, Norwegian University of Science and Technology, Trondheim, Norway, Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway
⨯
Yongqian Shu ,

* E-mail: yongqianshu@126.com (YS); zhulingjun@njmu.edu.cn (LZ)

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯
Lingjun Zhu

* E-mail: yongqianshu@126.com (YS); zhulingjun@njmu.edu.cn (LZ)

Affiliation Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⨯

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study

Xiaofeng Chen,
Quan Zhu,
Yiqian Liu,
Ping Liu,
Yongmei Yin,
Renhua Guo,
Kaihua Lu,
Yanhong Gu,
Lianke Liu,
Jinghua Wang

Published: May 16, 2014
https://doi.org/10.1371/journal.pone.0095897

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Point mutation
Is the Subject Area "Point mutation" applicable to this article?

Thanks for your feedback.
Diarrhea
Is the Subject Area "Diarrhea" applicable to this article?

Thanks for your feedback.
Adenocarcinoma
Is the Subject Area "Adenocarcinoma" applicable to this article?

Thanks for your feedback.
Chemotherapy
Is the Subject Area "Chemotherapy" applicable to this article?

Thanks for your feedback.
Retrospective studies
Is the Subject Area "Retrospective studies" applicable to this article?

Thanks for your feedback.